4.2 Article

Synthesis of 2-amino-4H-chromenes catalyst-free via sequential Knoevenagel-Michael reaction and evaluation of biological activity in tumor cells

Journal

MEDICINAL CHEMISTRY RESEARCH
Volume 32, Issue 10, Pages 2234-2244

Publisher

SPRINGER BIRKHAUSER
DOI: 10.1007/s00044-023-03131-w

Keywords

2-amino-4H-chromenes; Knoevenagel-Michael; Anticancer activity; Virtual screening; Molecular docking

Ask authors/readers for more resources

This work investigated solvents for the catalyst-free synthesis of 2-amino-4H-chromenes from salicylaldehydes and malononitrile. The use of ethanol under reflux conditions resulted in the production of several 2-amino-4H-chromenes with high yields and short reaction time. Virtual screening and in vitro assays demonstrated the high potential of compound 5e as an antitumor agent, suggesting a possible mechanism of action involving inhibition of the mutant T315l Abl protein. This study provides a promising starting point for the development of new antitumor agents.
This work focuses on investigating solvents for the catalyst-free synthesis of 2-amino-4H-chromenes from salicylaldehydes and malononitrile through the Knoevenagel-Michael sequential reaction. The use of ethanol under reflux conditions resulted in the production of several 2-amino-4H-chromenes 5(a-g) with high isolated yields (75-93%) within a short reaction time (60-300 min). Notably, four new compounds, 2-amino-4H-chromenes 5(b,d,e,g), were synthesized for the first time. Virtual screening was performed on the most promising molecules (5b, 5e, and 5 f) against cell lines H-116 and K-562, with 5e demonstrating the most potential in antitumor activity. The in vitro assays validated the high potential exhibited by the 5e molecule, corroborating the in silico findings. Molecular docking analysis suggested a possible mechanism of action for the 5e molecule involving inhibition of the mutant T315l Abl protein. Mutations in the kinase domain of Bcr-Abl commonly lead to resistance to imatinib therapy in chronic myelogenous leukemia patients. This study represents the first investigation into the biological activity of this compound class, offering a promising starting point developing of new antitumor agents.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available